A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

This study is testing a combination of three drugs — selinexor, temozolomide (a chemotherapy), and an anti-PD-1 immunotherapy — for patients with a rare type of brain and spinal lymphoma called primary central nervous system lymphoma (PCNSL) that has returned or stopped responding to treatment. **You may be eligible if...** - You are aged 18–75 with confirmed B-cell PCNSL - Your lymphoma has come back or stopped responding to at least one prior treatment including methotrexate - You have at least one measurable tumor on MRI - Your blood counts, liver, kidney, and clotting function are within acceptable ranges - Your overall health status is good enough to participate **You may NOT be eligible if...** - You have active brain infection, uncontrolled seizures, or severe neurological conditions - You have received prior anti-PD-1/PD-L1 therapy - You have active hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding - You have had a stem cell transplant Talk to your doctor to see if this trial is right for you.